Mitochondrial metabolic reprogramming drives diabetic kidney disease progression: cell-specific mechanisms, metabolic memory, and targeted strategies.

Lingfei Zhang, Yue Zhang, Liu Han, Jialei Wang, Lijie Hou, Songbo Fu

Abstract readReview

In one paragraph

Review in Molecular medicine (Cambridge, Mass.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lingfei Zhang *Lanzhou University CuiYing Honors College, Lanzhou University, Lanzhou, 730000, China.

Yue Zhang *The First Clinical Medical College, Lanzhou University, Lanzhou, 730000, China.

Liu HanThe First Clinical Medical College, Lanzhou University, Lanzhou, 730000, China.

Jialei WangThe First Clinical Medical College, Lanzhou University, Lanzhou, 730000, China.

Lijie HouDepartment of Endocrinology, First Hospital of Lanzhou University, Lanzhou, Gansu, 730000, China.

Songbo FuThe First Clinical Medical College, Lanzhou University, Lanzhou, 730000, China. ery_fusp@lzu.edu.cn.

Funding

14th Five-Year Plan Project 2023YF2508305Cuiying Scholars Research Cultivation Program CYXZPT2025-31Gansu Provincial Joint Research Fund Project 23JRRA1490Integrated Traditional Chinese and Western Medicine Collaborative Chronic Disease Management Research Project CXZH2024082Lanzhou University Innovation and Entrepreneurship training program 20260060119National Key Research and Development Program of China 2023YFC3503400National Natural Science Foundation of China 82560163

6 · The paper itself

Abstract

Diabetic Kidney Disease (DKD), as a major microvascular complication of diabetes, is the leading cause of chronic kidney disease and end-stage kidney disease. Metabolic reprogramming is an important concept in cancer research, and the most classic example is the Warburg effect. This phenomenon has also been observed in DKD, suggesting that metabolic reprogramming also plays a significant role in DKD. Mitochondria are crucial in both catabolism and anabolism, making them the center of metabolic reprogramming research. Additionally, mitochondria are involved in methylation and acetylation modifications, potentially playing a vital role in "metabolic memory." Starting from the metabolic landscape of mitochondria in cells, this review discusses mitochondrial metabolic reprogramming in different types of renal and immune cells, providing insights into the mechanisms underlying "metabolic memory." In addition, we comprehensively summarize therapeutic strategies targeting mitochondrial metabolic reprogramming from both preclinical and clinical perspectives. Unlike previous studies that primarily focused on individual pathophysiological processes, this review integrates the intrinsic link between mitochondrial metabolic reprogramming and epigenetic modifications associated with "metabolic memory," thereby offering a novel interdisciplinary perspective for overcoming current therapeutic bottlenecks in DKD.

Indexed as

Diabetic NephropathiesMetabolic ReprogrammingMitochondriaAnimalsDisease ProgressionEpigenesis, GeneticHumansDiabetic kidney diseaseMetabolic memoryMetabolic reprogrammingMitochondria

Identifiers

PMID42271221

DOI10.1186/s10020-026-01521-5

What Socratic holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.